Navigation Links
Amarin Corporation Appoints Colin W. Stewart as President and Chief Executive Officer
Date:8/17/2010

DUBLIN and MYSTIC, Conn., Aug. 17 /PRNewswire-FirstCall/ -- Amarin Corporation plc (Nasdaq: AMRN), a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today announced that Colin W. Stewart has been appointed President, Chief Executive Officer (CEO) and a member of the Company's Board of Directors effective August 16, 2010.  Mr. Stewart will be responsible for driving forward the Company's strategy to maximize the value of its lead product, AMR101, a new drug being studied in Phase 3 clinical trials for the treatment of high triglycerides. The Company announced last week that one of its Phase 3 trials, the MARINE trial, completed patient enrollment and randomization earlier than expected with top-line results now expected in early 2011.  

Mr. Stewart has more than 30 years of experience in executive management and commercial positions for pharmaceutical companies, including five years as President and CEO of CollaGenex Pharmaceuticals, Inc. where he was responsible for the company's growth leading to its successful sale in 2008.  

In addition, Mr. Stewart served ten years with the ASTA Medica Group, where he managed several business units in the United States and internationally. He began his career in sales and marketing for Winthrop Laboratories, Ltd. in the United Kingdom, and subsequently held a number of positions of increasing responsibility within the Sterling-Winthrop Group.

Dr. Declan Doogan, who has been serving as the Company's Interim CEO, will continue to support the Company as Chief Medical Officer providing Amarin access to the majority of his time.

Amarin's Chairman of the Board, Joseph Zakrzewski, commented, "We are very excited by the addition of Colin Stewart to the Amarin team.  He brings a wealth of commercial and executive management experience, which complements the already strong t
'/>"/>

SOURCE Amarin Corporation plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Amarin Proceeding to Phase 3 With AMR101 for Hypertriglyceridemia
2. Medco Announces Agreement to Acquire United BioSource Corporation: A Global Medical Research and Scientific Services Leader to Advance Drug Safety and Knowledge
3. Microfluidics International Corporation to Report Second Quarter 2010 Financial Results on August 10, 2010
4. Volcano Corporation Presentation at Canaccord Genuity Growth Conference to be Webcast
5. Kensey Nash Corporation Announces Its Fourth Quarter and Fiscal Year End 2010 Earnings Release Date and Teleconference
6. DURECT Corporation Invites You to Join Its Second Quarter 2010 Earnings Conference Call
7. Oxford Finance Corporation Leads $30 Million Secured Loan Facility for Cadence Pharmaceuticals
8. CVS Caremark Corporation to Hold Conference Call to Discuss:
9. NOVT Corporation Completes Reverse/Forward Stock Split
10. Sysmex America and Medica Corporation Announce Distribution Partnership
11. Cardiogenesis Corporation to Report 2010 Second Quarter Results on August 4th
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Tegra Medical is very pleased to announce the appointment of ... Executive Officer.  Mark was promoted from his current role of ... four facilities in Massachusetts , ... Medical in 2012 with 20+ years of broad-based operations, sales, ...
(Date:1/15/2014)... 2014  Echo Therapeutics, Inc. (Nasdaq: ECTE ) ... System as a non-invasive, wireless continuous glucose monitoring system, ... Chairman and Interim CEO of Echo Therapeutics, will present ... Conference. Mr. Doman will make a ...
(Date:1/15/2014)... to Millennium Research Group (MRG), the global authority ... United States and European transcatheter embolization ... through 2022, with embolization particles representing one of ... drug-eluting beads (DEBs) and radioembolization spheres in interventional ...
Breaking Medicine Technology:Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3
... Improved Long-term [Five-years],Overall Survival for these Seriously ... -- FOLFOX4, an,Eloxatin(R)-based chemotherapy regimen, provided significant,improvements ... and,time to disease progression (TTP) - a ... with metastatic (advanced) colorectal cancer.,Importantly, the FOLFOX4 ...
... Presented at Society of Nuclear,Medicine Annual Meeting ... Inc. , a biopharmaceutical company focused on,developing ... serious,diseases, today announced that its anti-carcinoembryonic antigen,(CEA) ... found to be safe and active when ...
Cached Medicine Technology:Eloxatin (oxaliplatin injection)-Based Chemotherapy Sets New,Treatment Benchmark in Patients With Metastatic Colorectal Cancer 2Eloxatin (oxaliplatin injection)-Based Chemotherapy Sets New,Treatment Benchmark in Patients With Metastatic Colorectal Cancer 3Eloxatin (oxaliplatin injection)-Based Chemotherapy Sets New,Treatment Benchmark in Patients With Metastatic Colorectal Cancer 4Repeated Radioimmunotherapy With 131I-Labetuzumab Appears Safe and,Effective in Colorectal Cancer with Liver Metastases 2Repeated Radioimmunotherapy With 131I-Labetuzumab Appears Safe and,Effective in Colorectal Cancer with Liver Metastases 3Repeated Radioimmunotherapy With 131I-Labetuzumab Appears Safe and,Effective in Colorectal Cancer with Liver Metastases 4Repeated Radioimmunotherapy With 131I-Labetuzumab Appears Safe and,Effective in Colorectal Cancer with Liver Metastases 5
(Date:7/9/2014)... A study published in the scientific journal ... Bonin, two researchers at Universit Laval, reveals that it ... method that involves rekindling pain so that it can ... means to alleviate chronic pain. , The researchers from ... universitaire en sant mentale de Qubec (IUSMQ) were inspired ...
(Date:7/9/2014)... the Keck School of Medicine of the University ... lacking a specific component of the immune system ... complication of infection. The discovery suggests that blocking ... in human autoimmune and hyper-inflammatory diseases such as ... study was published online on June 23 in ...
(Date:7/8/2014)... Memory Restoration has been awarded up to $15 million ... a four -year project aiming to help brain-injured people ... in neurosurgery, engineering, neurobiology, psychology and physics will collaborate ... in the brain. , Memory is the process in ... information, store it and retrieve it. Certain types of ...
(Date:7/8/2014)... A team of clinicians from Plymouth, UK, and Sydney, ... 10th July Australia) launched ACEmobile - a free-to-use app ... , ACEmobile is the first of its kind; an ... tool provides support through the whole process, meaning more ... out this type of assessment. Designed by clinicians for ...
(Date:7/8/2014)... 2014 In a study published yesterday in the ... La Jolla Institute (LJI) led by Pandurangan Vijayanand, Ph.D. identify ... currently affects over 200 million people world wide. , ... be divided into small sections or ,neighborhoods., Scientists can ... primed for gene production, by looking for a marker on ...
Breaking Medicine News(10 mins):Health News:Discovery of a new means to erase pain 2Health News:DARPA awards UCLA $15 million to restore lost memory 2Health News:DARPA awards UCLA $15 million to restore lost memory 3Health News:New app widens opportunities for dementia assessments 2Health News:New app widens opportunities for dementia assessments 3Health News:LJI develops new approach to identify genes poised to respond in asthma patients 2
... INDIANAPOLIS and MINNEAPOLIS, Aug. 19 WellPoint, Inc. (NYSE: ... RedBr i ck Hea l th ... entered into a strategic collaboration to create a new, behavior-based wellness ... health plan customers. , , Through an upcoming ...
... , WINSTON-SALEM, N.C., Aug. 19 A ... red blood cells, is now broadly available for the first time ... While scientists have long known of the benefits of fish and ... has proven that the omega-3 fatty acids found in fish dramatically ...
... , MURRIETA, Calif., Aug. 19 Forterus Inc. (Pink ... alcohol rehabilitation and other behavioral healthcare services, announced today revenues increased ... ended June 30, 2009 compared to revenues of $1.04 million, or ... , Forterus announced net income of $32,921, or $0.002 ...
... , LANHAM, Md., Aug. 19 ... immunization awareness campaign, Protecting our Future: The COSHAR Foundation ... new materials, including updated information about autism and vaccines and ... now. , , Through this ...
... modern drug, but not the most common, experts say, , ... remedy called "thunder god vine" helps reduce inflammation in people ... is an extract of the medicinal plant Tripterygium wilfordii ... gong teng" -- and has been used for centuries to ...
... , , NASHVILLE, ... managed care market intelligence, reports that while commercial pharmacy ... July 2008 and January 2009, commercial pharmacy benefit enrollment ... only a two percent decline over the same time ...
Cached Medicine News:Health News:WellPoint Collaborates with RedBrick Health to Create Integrated, Behavior-Based Wellness and Incentives Programs 2Health News:WellPoint Collaborates with RedBrick Health to Create Integrated, Behavior-Based Wellness and Incentives Programs 3Health News:WellPoint Collaborates with RedBrick Health to Create Integrated, Behavior-Based Wellness and Incentives Programs 4Health News:New Omega-3 Blood Test: A Better Predictor of Coronary Heart Disease Than Cholesterol 2Health News:New Omega-3 Blood Test: A Better Predictor of Coronary Heart Disease Than Cholesterol 3Health News:New Omega-3 Blood Test: A Better Predictor of Coronary Heart Disease Than Cholesterol 4Health News:Forterus Inc. Posts Revenue, Net Income Gains 2Health News:COSHAR Foundation Enhances National Childhood Immunization Awareness Campaign 2Health News:Herb Shows Potential for Rheumatoid Arthritis 2Health News:Herb Shows Potential for Rheumatoid Arthritis 3Health News:Miami-Area Experienced Fewer Fluctuations in Pharmacy Benefit Enrollment Than Other Florida Markets 2
This legless table has adjustable height and round post. Pad sold separately....
This table has adjustable height, an integral leg, and blade post. Includes a standard 2" (5 cm) pad....
This table has adjustable height, round post, and universal clamp. Replacement 1" (5 cm) or 2" (2.5 cm) pad sold separately....
... An excellent choice for orthopedic procedures. ... width to 24" for the ... clamps quickly attach to any O.R. ... easy C-Arm access and stability. ...
Medicine Products: